Niraparib: A Review in Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0582-1
Abstract: Niraparib (Zejula®), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based… read more here.
Keywords: peritoneal cancer; tube primary; fallopian tube; ovarian fallopian ... See more keywords
Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice
Sign Up to like & getrecommendations! Published in 2025 at "Biomedicines"
DOI: 10.3390/biomedicines13020483
Abstract: Background: High-grade advanced ovarian, fallopian tube, and primary peritoneal (HGAOC) cancers require both surgical and systemic treatment. The introduction of polyADP-ribose polymerase inhibitors (PARPis) has significantly improved outcomes. This study presents an analysis of HGAOC… read more here.
Keywords: high grade; advanced ovarian; tube primary; grade advanced ... See more keywords